LYST and neoplasm: Although the results are promising, it should be mentioned that further comprehensive in vivo studies are essential to validate the therapeutic viability of the Cu(BDC)/ChS system in terms of biodistribution, tumor targeting efficiency, pharmacokinetics, and long-term safety in biological systems.